Biologics and biosimilars in musculoskeletal diseases: addressing regulatory inconsistencies and clinical uncertainty
Biologics are complex protein-based medications derived from living organisms, used primarily to treat immune-related diseases. Unlike small-molecule drugs synthesized from chemicals, biologics are produced using advanced biotechnology, making their replication difficult. Biosimilars are nearly iden...
Saved in:
| Main Authors: | Lauren N. McGrath, David Moodie, Steven R. Feldman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2025-07-01
|
| Series: | Exploration of Musculoskeletal Diseases |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/uploads/Article/A100798/100798.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety of Switching from a Reference Biologic to Its Biosimilar: A Systematic Review and Meta-Analysis
by: Sarah Saad Aljahili, et al.
Published: (2025-02-01) -
Evaluation of rheumatologists’ knowledge of biosimilars
by: Thayane Furtado Rolim Lima, et al.
Published: (2025-07-01) -
Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers
by: Fernando Perez-Ruiz, et al.
Published: (2024-09-01) -
Biosimilars, the journey has begun
by: Alba Martos-Rosa, et al.
Published: (2015-01-01) -
Bridging the gap: The future of biosimilars regulations
by: Anan S. Jarab, et al.
Published: (2024-12-01)